Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Inclusion Criteria:

- The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung
cancer and/or pancreatic cancer with or without a KRAS mutation.

- Tumor progression following at least one prior standard therapy, the subject refuses
standard therapy, or no standard therapy exists.

- The subject has a radiographically measurable tumor.

- The subject is able to carry out daily life activities without difficulty.

- The subject is able to swallow and retain oral medication.

- The subject does not have significant side effects from previous anti-cancer
treatment.

- The subject has adequate organ and blood cell counts.

- Sexually active subjects must use medically acceptable methods of contraception
during the course of the study.

Exclusion Criteria:

- The subject has had major surgery or received certain types of cancer therapy within
2-3 weeks before starting the study.

- The subject has a brain tumor.

- Current severe, uncontrolled systemic disease.

- History of clinically significant heart, lung, or eye/vision problems.

- The subject has high blood pressure that is not well-controlled with medication.

- The subject has a permanent pacemaker.

- The subject is pregnant or breastfeeding.

- Positive for Hepatitis B, Hepatitis C, or HIV.